Anti-HCC T-cell immunity may be elicited via the abnormal expression of oncofetal and cancer testis antigen genes (AFP, GPC3, MAGE-1 and NYESO1), viral peptide, or tumour-specific neoantigens. Here, AFP is linked to neoplasm.